Scientists Discover New Molecule of the Immune System; a Chemokine That Binds One of The HIV Co-receptors.

Business Editors/Health & Medial Writers

BIOWIRE2K

SAN FRANCISCO & TEL AVIV, Israel--(BW HealthWire)--Oct. 5, 2000

A team of scientists at the University of California, San Francisco and Compugen Ltd. (Nasdaq:CGEN) has discovered a new molecule of the immune system -- a member of a family of proteins called chemokines which recruit the body's army of defensive immune cells to sites of invasion.

The new chemokine is only the second one ever detected that is "tethered" within the membrane of cells rather than being made in a diffusable form.

The research team used the chemokine as a molecular probe to identify its receptor. Although its association with a chemokine was a discovery, the receptor turned out to be one that had already been isolated by other researchers in cell studies as one of the receptors exploited by invading HIV viruses to gain entry into human cells.

The novel molecule was identified by researchers at the genomics and proteomics research company Compugen, and its biological role was described by UCSF scientists led by Jason Cyster, PhD, an investigator in the Howard Hughes Medical Institute and assistant professor of microbiology and immunology at UCSF. Cyster is senior author on a paper reporting the research in the October issue of Nature Immunology, co-authored by all the researchers.

In experiments with mouse tissues, the UCSF researchers determined that the novel chemokine, which they named CXCL16 (for 16th chemokine of the CXC subfamily) is produced by cells within the spleen and lymph nodes -- including the so-called dendritic cells which help trigger immune responses -- and also by cells in the spleen's red pulp.

Cytotoxic CD8 T cells, known for the ability to kill virally infected cells, were found to express the chemokine receptor and to be able to migrate towards a source of the chemokine. The researchers speculate that CXCL16 made by dendritic cells might be important in helping activate CD8 T cells to make them into fully functional killer cells. CXCL16 was also detected in some non-lymphoid tissues, including small intestine, lungs, liver and kidney, and in these sites it may help the activated CD8 cells carry out their killer function during infections.

In addition to CD8 T cells, the receptor was found on subpopulations of CD4 T cells, including a specialized population of CD4 T cells that live in the gut and that are known as intra-epithelial T cells. Cyster suggests that the chemokine may help restrain these specialized lymphocytes within the mucosa, ready to fight invaders. Mucosal surfaces are a port of entry for the HIV virus, and high expression of CXCL16 in the mucosa might influence the ability of infecting HIV particles to utilize the CXCL16 receptor as a co-receptor. Another specialized type of T cell, the Natural Killer T cell, was found to have high expression of the receptor. Others have shown an important role for these cells in responding to infections in spleen and liver, both sites where the chemokine is made.

Known by three names including Bonzo, the receptor had been termed an "orphan receptor" since its natural partner - which turns out to be the new chemokine -- had not been known. Now that its link with a chemokine has been identified, the scientists have renamed the receptor according to accepted nomenclature. Less flashy than Bonzo, the receptor's new name is CXCR6.

The chemokine was identified using Compugen's LEADS algorithm-driven drug discovery platform, that uses large-scale analysis of expressed human DNA to find new sequences similar to those already known in other protein families. This approach led to identification in public databases of a human gene that resembled the chemokine family of molecules. The similarity was extremely low, however, and it was likely for this reason that the sequence had laid in the public database unrecognized as a candidate chemokine by researchers using established sequence alignment-tools.

First author on the Nature Immunology paper is Mehrdad Matloubian, MD, PhD, a post-doctoral researcher working with Cyster at UCSF. Compugen scientists collaborated on the paper, along with Jay Ryan, MD, PhD, assistant professor of immunology at UCSF and a physician at the Veterans Administration Medical Center in San Francisco.

The UCSF research was funded by the NIH, the Packard Foundation and a UCSF Molecular Medicine Training Program.

Compugen (www.cgen.com) is a pioneer in the field of computational genomics and is developing new approaches to computational proteomics. Compugen combines the disciplines of mathematics and computer science with molecular biology to improve its understanding of genomics and proteomics. Compugen develops products and services that enable life scientists to significantly enhance and accelerate their research efforts in the discovery of drugs, therapeutics, diagnostics and agricultural products. Compugen provides its corporate solutions to pharmaceutical, biotechnology and other life science organizations such as Pfizer, Human Genome Sciences, Inc. and the U.S. Patent and Trademark Office. In addition, Compugen provides these products and services to molecular biologists and other life scientists through its LabOnWeb.com Web site. Compugen is also commercializing the genes and proteins that it discovers through its Novel Genomics division.

This press release contains "forward-looking statements." These statements include speculations regarding the possible utility of the CXCL16 chemokine, and other statements that include words like "may," "expects," "believes," and "intends," and that describe opinions about future events. These forward-looking statements are subject to risks and uncertainties that may cause the actual results, performance or achievements of Compugen to be materially difference from any future results, performance or achievements expressed or implied by such forward-looking statements. Some of these risks are: changes in relationships with collaborators; the impact of competitive products and technological changes; risks relating to the development of new products; the ability to implement technological improvements; the ability of Compugen to obtain and retain customers. These and other factors are identified and more fully explained under the heading "Risk Factors" in Compugen's Registration Statement on Form F-1 filed with the Securities and Exchange Commission.

Released jointly by the University of California,

San Francisco and Compugen, Ltd.